Pfizer chalked up a key win in its legal battle surrounding the now-recalled smoking cessation drug Chantix after a New York ...
Elsewhere at the pharma’s ASCO booth, Novartis is also adding a mixed-reality aspect to its long-running “More Than Just ...
Stimulants are typically the go-to option for doctors prescribing treatments for attention-deficit hyperactivity disorder ...
After half a decade spent developing an automated manufacturing platform, Ori Biotech believes it's ready to make a mark on ...
Neurocrine Biosciences’ dealmaking prospects may soon get another round of attention with the installment of a new CEO.  | ...
While several CDMO giants have been weathering an industry slowdown in recent years following the pandemic and longing for ...
Amgen has made waves in the biosimilar field in recent years with its U.S.-first Humira biosim launch last year and its ...
In the FDA’s push to grant accelerated approvals to treatments that can help patients in need, the agency has become ...
A recently announced $900 million restructuring drive is already making waves at Takeda, wi | From early July to March 2025, ...
Bolstered by a full FDA approval for its primary immunoglobulin A nephropathy (IgAN) treatment Tarpeyo, Calliditas has earned ...
Novartis is eyeing an FDA filing for a second drug in immunoglobulin A nephropathy (IgAN), as the Swiss pharma goes all-in on ...
A data breach at drug distributor Cencora has left sensitive information vulnerable, with patients on medicines from a dozen ...